Data Sheet 1_Impact of post-resistance molecular retesting strategies on treatment timeliness and clinical outcomes in EGFR-mutant advanced NSCLC: a real-world study.docx

A 1:1:1 propensity score–matched analysis and sensitivity analyses restricted to patients who initiated second-line therapy within 28 or 30 days after progression were performed.</p>Results<p>Among 229 patients, median TTI was shorter with ctDNA than tissue NGS (11.0 vs. 20.5 days, P < 0.001). Subsequent targeted therapy was most frequently used in the ctDNA group (95.9%), followed by the tissue NGS (89.4%) and no-retesting groups (81.4%; P = 0.039).

After matching, median 2L-PFS was 5.0, 9.0, and 9.0 months in the no-retesting, tissue NGS, and ctDNA groups, respectively (overall P = 0.005). Median 2L-OS was 12.0, 20.0, and 19.0 months, respectively (overall P = 0.074). No significant differences in 2L-PFS or 2L-OS were observed between ctDNA and tissue NGS, and findings were consistent in 28- and 30-day sensitivity analyses.</p>Conclusions<p>Compared with tissue NGS, ctDNA testing was associated with shorter TTI, with no significant differences in 2L-PFS or 2L-OS.

The ctDNA group had the highest observed targeted therapy use.</p>